Efficacy and Safety of keepMED Positive Airway Pressure Device in Patients With Obstructive Sleep Apnea (keePaOSA)

KeepMED-away-Obstructive Sleep Apnea Trial: Efficacy and Safety of keepMED Positive Airway Pressure Device in Patients With Obstructive Sleep Apnea - keePaOSA

A prospective, multi-centre, single-arm, open-label, interventional study with a non-marketed medical device.

The primary study objective is to assess the efficacy of the keepMED PAP device on modification of respiratory characteristics in patients with OSA at one therapy night in a sleep lab.

Secondarily, the safety of the use of the device in this setting is assessed.

Study Overview

• Status: Not yet recruiting
• Conditions: Obstructive Sleep Apnea
• Intervention / Treatment: Device: keepMED PAP device

Detailed Description

The study includes a baseline visit, a habituation night, and a therapy night. Both nights will be undertaken in the sleep lab under identical conditions and will include the keepMED PAP therapy activated in parallel to polysomnography (PSG).

Baseline diagnostic PSG, performed within one month prior to enrollment to the study, will be used to assess the device efficacy.

An interim analysis to re-estimate the sample size will be performed after availability of data of 50% enrolled and treated study patients. The sample size will be re-estimated based on the observed changes of AHI in the interim analysis.

• Study Type: Interventional
• Enrollment (Anticipated): 65
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Pierre-Charles Neuzeret, PhD; Phone Number: +49 152 554 22500; Email: pierre-charles@keepmed.com
• Study Contact Backup: Name: Alex Rapoport; Phone Number: +972 3 5170837; Email: alex@keepmed.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Age ≥18 years.

Newly diagnosed OSA with AHI ≥ 15 events/hours.

Indication for OSA PAP therapy in routine clinical care according to applicable medical guidelines within one month prior to study enrolment.

Naïve to PAP therapy, i.e. even no PAP therapy during a PSG night.

Weight > 30kg.

Signed informed consent.

Exclusion Criteria:

Body Mass Index (BMI) of ≤20 kg/m² or ≥ 35 kg/m².

Pathologically low blood pressure (systolic ≤90mm Hg; diastolic ≤60 mm Hg).

Current unstable or serious medical conditions (such as angina pectoris, myocardial infarction, cancer, stroke, dementia, congestive heart failure) which based on the physician's judgment might put the patient at high risk.

Mixed and central apnea index ≥ 5 events/hour in PSG without PAP therapy.

Bullous lung disease.

Tracheostomy.

Pneumothorax.

Pneumocephalus.

Cerebrospinal fluid leak.

Current sinus or middle ear infection.

Persistent blockage of one or both nostrils (including nasal septum deviation and nasal polyps) or any other reason that leads to difficulty of breathing through the nose while awake.

Any nasal, facial or head abnormalities that would not allow adequate placement of the device.

Previous diagnosis of insomnia, narcolepsy or periodic limb movement disorder that in the judgment of the clinician could affect sleep quality assessment.

Chronic respiratory disease (COPD, pulmonary fibrosis or asthma) or FEV/FVC ≤ 60% in history.

History of respiratory failure.

Supplemental oxygen is required.

Uvulopalatopharyngoplasty or other surgical procedure to correct apnea.

Acute respiratory infection.

Subject recovered from Covid-19 but suffers from on-going symptoms or when subject's Covid-19 illness history can affect the study outcome based on the physician's judgment.

Pregnancy.

Medication that may alter sleep architecture.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: treatment with keepMED PAP device; Therapy night is performed with the keepMED PAP during a polysomnography in the sleep lab

Device: keepMED PAP device; The keepMED PAP device is an automatic, wearable positive airway pressure device indicated for treatment of obstructive sleep apnea. A therapeutic pressure is delivered to the patient upper airway through a nasal interface. It is similar to other marketed positive airway pressure devices with respect to its fundamental use of positive airway pressure for the treatment of sleep apnea as well as with regard to its functional components and accessories (e.g., a PAP unit, a mask/nasal interface, an air filter, tubing, etc.).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes of Apnea Hypopnea Index (AHI)	Efficacy by means of changes of the AHI comparing baseline measures in a sleep lab night without keepMED PAP therapy with measures during one therapy night in a sleep lab.	A single therapy night compared to baseline (conducted approx 1 month before the therapy night)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in oxygen desaturation index (ODI)	Changes in ODI comparing baseline measures in a sleep lab night without keepMED PAP therapy with measures during one therapy night in a sleep lab	A single therapy night compared to baseline (conducted approx 1 month before the therapy night)
Changes in arousal index (sleep quality)	Changes in arousal index comparing baseline measures in a sleep lab night without keepMED PAP therapy with measures during one therapy night in a sleep lab	A single therapy night compared to baseline (conducted approx 1 month before the therapy night)
Number of adverse events	Safety of the device use by means of adverse events in patients using the keepMED PAP device	Throughout the study, an average of 2-7 days per subject

Collaborators and Investigators

• Sponsor: keepMED Ltd.
• Collaborators: CRI-The Clinical Research Institute GmbH
• Investigators: Principal Investigator: Jean-Louis Pépin, Prof, CHU Michallon Laboratoire EFCR CS 10217

Study record dates

Study Major Dates

• Study Start (Anticipated): September 14, 2021
• Primary Completion (Anticipated): January 15, 2022
• Study Completion (Anticipated): February 28, 2022

Study Registration Dates

• First Submitted: April 28, 2021
• First Submitted That Met QC Criteria: May 2, 2021
• First Posted (Actual): May 6, 2021

Study Record Updates

• Last Update Posted (Actual): September 2, 2021
• Last Update Submitted That Met QC Criteria: September 1, 2021
• Last Verified: May 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Respiratory Tract Diseases; Respiration Disorders; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Signs and Symptoms, Respiratory; Sleep Apnea Syndromes; Sleep Apnea, Obstructive; Apnea
• Other Study ID Numbers: CLN-210423-00

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No